Inhibrx Biosciences, Inc.
NASDAQ:INBXBiotechnology
-$2.58 today
- Market cap
- $1.02B
- Beta
- 3.32
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$8.35
Volume 0.29M
Average 0.43M
INBX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Inhibrx Biosciences, Inc.NASDAQ: INBX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $33.44M (cash outflow) fell 22.8% year over year, ahead of the -107.7% change in trailing-twelve-month net income. Sequentially, it rose 1.8% from the prior quarter. Over 3 fiscal years it compounded at -1.2% a year.
Context
- Net income amounted to 10773.5% of revenue in FY2025, down 833012.5 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$144.61M (+3.3%) for the fiscal year ending Dec 2026, a step up from the -108.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$33.44M+1.8% QoQ
- Last fiscal yearDec 2025
- -$140.06M-108.3% YoY
- LTMMar 2026
- -$130.19M-107.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -22.8% | +24.7% | +47.5 pp |
| 1 year | -108.3% | +3.3% | +111.6 pp |
| 3-year CAGR | -1.2% | -22.6% | -21.4 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (140.06M) USD
- Year-over-year change
- -108.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (140.06M) | -108.3% |
| FY2024 | 2024-12-31 | 1.69B | +804.0% |
| FY2023 | 2023-12-31 | (239.73M) | -65.1% |
| FY2022 | 2022-12-31 | (145.23M) | -77.6% |
| FY2021 | 2021-12-31 | (81.77M) | — |
Net Income vs competitors
How INBX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -107.7% is the lowest of 7, against a peer median of +42.5%.
- Net income amounts to 10014.2% of revenue for INBX, versus a peer median of 699.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $309.06M USD | +37.6% | +32.1% | 275948.2% | |
GENBGenerate Biomedicines, Inc. | FY2025 | $222.97M USD | +22.9% | — | 699.1% |
| LTM Mar 2026 | €217.14M EUR | +906.0% | — | 582.2% | |
| LTM Mar 2026 | $130.19M USD | -107.7% | -1.2% | 10014.2% | |
| LTM Mar 2026 | $118.44M USD | +10.2% | +3.2% | 6450.8% | |
TECXTectonic Therapeutic, Inc. | LTM Mar 2026 | $115.3M USD | +96.5% | +1220.8% | — |
| LTM Mar 2026 | $114.48M USD | +47.3% | +21.7% | 529.7% | |
| Peer median (excluding INBX) | — | +42.5% | +26.9% | 699.1% | |
Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (81.77M) | (145.23M) | (239.73M) | 1.69B | (140.06M) |
| Depreciation & Amortization | 1.2M | 1.23M | 1.19M | 2.29M | 2.48M |
| Deferred Income Tax | (9K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 15.05M | 20.45M | 24.85M | 58.52M | 11.14M |
| Change in Working Capital | (17.52M) | 3.16M | 15.35M | 52.05M | (7.61M) |
| Accounts Receivables | (167K) | 130K | (521K) | 381K | 243K |
| Inventory | (11.03M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.64M) | (705K) | 2.11M | 17.9M | (3.3M) |
| Other Working Capital | (1.67M) | 3.74M | 13.76M | 33.77M | (4.56M) |
| Other Non-Cash Items | 2.73M | 5.09M | 5.03M | (1.99B) | 4.25M |
| Operating Cash Flow | (80.32M) | (115.3M) | (193.31M) | (194.41M) | (129.79M) |
| Capital Expenditures | (864K) | (686K) | (4.59M) | (2.6M) | (31K) |
| Acquisitions (Net) | 55K | 0 | 0 | 0 | 3K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (809K) | (686K) | (4.59M) | (2.6M) | (28K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 99.84M |
| Common Stock Issued | 40.2M | 129.74M | 201.96M | 71.68M | 1.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 83.77M | 128.81M | 0 | 0 | 0 |
| Financing Cash Flow | 83.77M | 258.55M | 201.96M | 71.68M | 101.45M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 2.64M | 142.56M | 4.06M | (125.33M) | (28.38M) |
| Free Cash Flow | (81.19M) | (115.99M) | (197.9M) | (197.01M) | (129.83M) |
Inhibrx Biosciences, Inc.
NASDAQ:INBX
Intrinsic Alpha fair value
Locked
Current Price
$69.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.